The Prevalence of Benzodiazepine Use among Italian Drivers in 15,988 Cases of Driving License Regranting from 2015 to 2023: Risks and Implications for Driving Fitness

Author:

Stefani Lucrezia12ORCID,Mineo Federico1ORCID,Romani Leonardo12,Vernich Francesca1ORCID,Russo Carmelo12ORCID,Marsella Luigi Tonino1,Tittarelli Roberta1ORCID

Affiliation:

1. Laboratory of Forensic Toxicology, Section of Legal and Forensic Medicine, Social Security and Forensic Toxicology, Department of Biomedicine and Prevention, Faculty of Medicine and Surgery, University of Rome “Tor Vergata”, Via Montpellier 1, 00133 Rome, Italy

2. PhD School in Medical-Surgical Applied Sciences, University of Rome “Tor Vergata”, Via Montpellier 1, 00133 Rome, Italy

Abstract

The use of benzodiazepines is strongly associated with an increased risk of traffic accidents due to their side effects of sedation and drowsiness, which can significantly impair driving performance. The main aim of our study was to investigate the trend of benzodiazepine use over nine years (2015–2023) in a population of 15,988 subjects who had their license suspended for driving under the influence (DUI) of alcohol or drugs. Among the 15,988 users accessed to our laboratory, 924 tested positive for at least one benzodiazepine. An increase in the number of positive-testing users was observed in the period 2015–2018, followed by a slight decrease in 2019. Overall, the trend of benzodiazepine use was stable over the next four years (2020–2023), with the highest incidence in 2022. The most common benzodiazepines, and/or metabolites, found in urine samples were α-OH-alprazolam (28.66%; n = 366) and oxazepam (27.25%; n = 348). Several cases of mixed positivity were observed in the study population. The main substances taken with benzodiazepines were cocaine and Δ9-tetrahydrocannabinol. Our findings suggest that people taking benzodiazepines should be monitored, as these have a relevant impact on driving ability in addition to significant interindividual differences in the behavioral effects of benzodiazepines on driving performance.

Publisher

MDPI AG

Reference50 articles.

1. Benzodiazepines: Uses, Dangers, and Clinical Considerations;Edinoff;Neurol. Int.,2021

2. (2023, June 27). EMCDDA New Benzodiazepines in Europe—A Review. Available online: https://www.emcdda.europa.eu/publications/rapid-communications/new-benzodiazepines-europe-review_en.

3. World Health Organization (WHO) (2023, June 27). Mental Disorders. Available online: https://www.who.int/news-room/fact-sheets/detail/mental-disorders.

4. European Monitoring Centre for Drugs and Drug Addiction (2023). European Drug Report 2023: Trends and Developments, European Monitoring Centre for Drugs and Drug Addiction.

5. Public Health Scotland Rapid Action Drug Alerts and Response (RADAR) (2024). Quarterly Report, Public Health Scotland.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3